TY - JOUR
T1 - Insulin-like growth factor-1 receptor overexpression is associated with outcome in invasive urothelial carcinoma of urinary bladder
T2 - A retrospective study of patients treated using radical cystectomy
AU - Gonzalez-Roibon, Nilda
AU - Kim, Jenny J.
AU - Faraj, Sheila F.
AU - Chaux, Alcides
AU - Bezerra, Stephania M.
AU - Munari, Enrico
AU - Ellis, Carla LaShannon
AU - Sharma, Rajni
AU - Keizman, Daniel
AU - Bivalacqua, Trinity J.
AU - Schoenberg, Mark
AU - Eisenberger, Mario
AU - Carducci, Michael
AU - Netto, George J.
N1 - Funding Information:
This study was partially supported by the Johns Hopkins Medicine–Patana Fund for Research and Clinical Innovator Award from Flight Attendant Medical Research Institute (FAMRI) Fund. Presented in part at the 2013 United States and Canadian (USCAP) Annual Meeting in Baltimore, USA.
PY - 2014/6
Y1 - 2014/6
N2 - Objective To assess the insulin-like growth factor-1 receptor (IGF1R) expression in urothelial carcinoma (UC) and its prognostic role in relation to clinicopathologic parameters. Methods A total of 100 cases of invasive UC were evaluated using tissue microarrays. Membranous IGF1R staining was evaluated using immunohistochemistry. A scoring method analogous to that of HER2 expression in breast carcinoma was used, and the highest score was assigned in each tumor. IGF1R was considered overexpressed in cases with score ≥1. Results We found IGF1R overexpression in 62% of invasive UC. IGF1R overexpression was associated with race (P =.04) and pT category (P =.03). Median follow-up was 29 months (range, 0.5-212). Progression rate was 60%, and overall mortality and cancer-specific mortality rates were 69% and 51%, respectively. In invasive UC, IGF1R overexpression was significantly associated with overall mortality and cancer-specific mortality (Mantel Cox P =.0002 and P =.006, respectively). IGF1R overexpression was associated with increased hazard ratios (HRs) for overall mortality (HR = 2.63, P =.001) and cancer-specific mortality (HR = 2.45, P =.01), independently and after adjusting for clinicopathologic features and treatment modalities. Conclusion We found IGF1R overexpression in 62% of bladder UC. More importantly, IGF1R overexpression was a significant predictor of overall mortality and cancer-specific mortality, suggesting its potential role as a prognosticator in UC of bladder.
AB - Objective To assess the insulin-like growth factor-1 receptor (IGF1R) expression in urothelial carcinoma (UC) and its prognostic role in relation to clinicopathologic parameters. Methods A total of 100 cases of invasive UC were evaluated using tissue microarrays. Membranous IGF1R staining was evaluated using immunohistochemistry. A scoring method analogous to that of HER2 expression in breast carcinoma was used, and the highest score was assigned in each tumor. IGF1R was considered overexpressed in cases with score ≥1. Results We found IGF1R overexpression in 62% of invasive UC. IGF1R overexpression was associated with race (P =.04) and pT category (P =.03). Median follow-up was 29 months (range, 0.5-212). Progression rate was 60%, and overall mortality and cancer-specific mortality rates were 69% and 51%, respectively. In invasive UC, IGF1R overexpression was significantly associated with overall mortality and cancer-specific mortality (Mantel Cox P =.0002 and P =.006, respectively). IGF1R overexpression was associated with increased hazard ratios (HRs) for overall mortality (HR = 2.63, P =.001) and cancer-specific mortality (HR = 2.45, P =.01), independently and after adjusting for clinicopathologic features and treatment modalities. Conclusion We found IGF1R overexpression in 62% of bladder UC. More importantly, IGF1R overexpression was a significant predictor of overall mortality and cancer-specific mortality, suggesting its potential role as a prognosticator in UC of bladder.
UR - http://www.scopus.com/inward/record.url?scp=84901604277&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84901604277&partnerID=8YFLogxK
U2 - 10.1016/j.urology.2014.01.028
DO - 10.1016/j.urology.2014.01.028
M3 - Article
C2 - 24713135
AN - SCOPUS:84901604277
SN - 0090-4295
VL - 83
SP - 1444.e1-1444.e6
JO - Urology
JF - Urology
IS - 6
ER -